Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study).

IF 2.8 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2025-06-01 Epub Date: 2025-04-21 DOI:10.1007/s10147-025-02759-5

Kenji Tanabe, Soichiro Yoshida, Tomoki Kimura, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto, Sho Uehara, Saori Araki, Masaharu Inoue, Ryoji Takazawa, Noboru Numao, Yukihiro Ohtsuka, Hajime Tanaka, Yasuhisa Fujii

{"title":"Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study).","authors":"Kenji Tanabe, Soichiro Yoshida, Tomoki Kimura, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto, Sho Uehara, Saori Araki, Masaharu Inoue, Ryoji Takazawa, Noboru Numao, Yukihiro Ohtsuka, Hajime Tanaka, Yasuhisa Fujii","doi":"10.1007/s10147-025-02759-5","DOIUrl":null,"url":null,"abstract":"Background: Oligo-metastatic urothelial carcinoma (OMUC), characterized by a limited number of metastases, demonstrates better survival outcomes compared to poly-metastatic urothelial carcinoma (PMUC), but some patients with OMUC exhibit poor prognosis. However, a comprehensive analysis of prognostic factors in OMUC remains lacking. This study aimed to determine prognostic factors in patients with OMUC from a multicenter dataset and evaluate the effect of existing predictive models.Methods: This retrospective study included 443 patients with metastatic urothelial carcinoma (MUC) from 15 institutions (YUSHIMA study). OMUC involved cases with three or fewer metastases. Clinical data were analyzed for associations with overall survival (OS) utilizing Cox regression models. The effect of existing predictive models (Bajorin, Bellmunt, and Apolo) on OMUC prognosis was evaluated.Results: Patients with OMUC (n = 182) demonstrated better Eastern Cooperative Oncology Group-performance status (ECOG-PS) and lower visceral metastasis frequency compared to PMUC (n = 261). Patients with OMUC exhibited a median OS of 26.1 months vs. 13.7 months for PMUC (p < 0.01). Poor ECOG-PS, liver metastasis, and hypoalbuminemia appeared as independent poor prognostic factors for OS in OMUC. The Bajorin, Bellmunt, and Apolo models significantly correlated with OS in patients with OMUC (p < 0.01, for all).Conclusion: Known prognostic factors for MUC were confirmed as significant prognostic factors for OS in OMUC, and existing prognostic models applied to OMUC. These results are expected to contribute to developing more effective treatment strategies for OMUC.","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1237-1246"},"PeriodicalIF":2.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02759-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Oligo-metastatic urothelial carcinoma (OMUC), characterized by a limited number of metastases, demonstrates better survival outcomes compared to poly-metastatic urothelial carcinoma (PMUC), but some patients with OMUC exhibit poor prognosis. However, a comprehensive analysis of prognostic factors in OMUC remains lacking. This study aimed to determine prognostic factors in patients with OMUC from a multicenter dataset and evaluate the effect of existing predictive models.

Methods: This retrospective study included 443 patients with metastatic urothelial carcinoma (MUC) from 15 institutions (YUSHIMA study). OMUC involved cases with three or fewer metastases. Clinical data were analyzed for associations with overall survival (OS) utilizing Cox regression models. The effect of existing predictive models (Bajorin, Bellmunt, and Apolo) on OMUC prognosis was evaluated.

Results: Patients with OMUC (n = 182) demonstrated better Eastern Cooperative Oncology Group-performance status (ECOG-PS) and lower visceral metastasis frequency compared to PMUC (n = 261). Patients with OMUC exhibited a median OS of 26.1 months vs. 13.7 months for PMUC (p < 0.01). Poor ECOG-PS, liver metastasis, and hypoalbuminemia appeared as independent poor prognostic factors for OS in OMUC. The Bajorin, Bellmunt, and Apolo models significantly correlated with OS in patients with OMUC (p < 0.01, for all).

Conclusion: Known prognostic factors for MUC were confirmed as significant prognostic factors for OS in OMUC, and existing prognostic models applied to OMUC. These results are expected to contribute to developing more effective treatment strategies for OMUC.

查看原文本刊更多论文

低转移性尿路上皮癌的预后因素及现有预测模型的影响（YUSHIMA研究）。

背景：低转移性尿路上皮癌（OMUC）的特点是转移数量有限，与多转移性尿路上皮癌（PMUC）相比，其生存结果更好，但一些OMUC患者预后较差。然而，对OMUC预后因素的综合分析仍然缺乏。本研究旨在从多中心数据集中确定OMUC患者的预后因素，并评估现有预测模型的效果。方法：本回顾性研究包括来自15个机构的443例转移性尿路上皮癌（MUC）患者（YUSHIMA研究）。OMUC涉及三个或更少转移的病例。使用Cox回归模型分析临床数据与总生存期（OS）的关系。评估现有预测模型（Bajorin、bellmont、Apolo）对OMUC预后的影响。结果：与PMUC （n = 261）相比，OMUC患者（n = 182）表现出更好的东部肿瘤合作组表现状态（ECOG-PS）和更低的内脏转移频率。OMUC患者的中位OS为26.1个月，而PMUC患者的中位OS为13.7个月（p < 0.01）。ECOG-PS差、肝转移和低白蛋白血症是OMUC OS的独立不良预后因素。OMUC患者的Bajorin、bellmont和Apolo模型与OS显著相关（p < 0.01）。结论：已知的OMUC预后因素是OMUC OS的重要预后因素，现有的预后模型适用于OMUC。预计这些结果将有助于制定更有效的OMUC治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.